Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanomaLuiza Martins Nascentes Melo, Iris Helfrich, Irem Oezel et al.|Journal for ImmunoTherapy of Cancer|2023Cited by 31
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanomaSara Egea‐Rodriguez, Iris Helfrich|Clinical and Translational Medicine|2025Cited by 2